The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Nanobodies as novel agents for cancer therapy
Abstract
Nanobodies are the smallest fragments of naturally occurring heavy-chain antibodies that have evolved to be fully functional in the absence of a light chain. As such, the cloning and selection of antigen-specific nanobodies obviate the need for construction and screening of large libraries, and for lengthy and unpredictable in vitro affinity maturation steps. The unique and well-characterised properties enable nanobodies to excel conventional therapeutic antibodies in terms of recognising uncommon or hidden epitopes, binding into cavities or active sites of protein targets, tailoring of half-life, drug format flexibility, low immunogenic potential and ease of manufacture. Moreover, the favourable biophysical and pharmacological properties of nanobodies, together with the ease of formatting them into multifunctional protein therapeutics, leaves them ideally placed as a new generation of antibody-based therapeutics. This review describes the state of the art on nanobodies and illustrates their potential as cancer therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Self-citationMaking antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P. T., & Winter, G. (1989) · Nature · doi:10.1038/341544a0 · Cited by 1,003
Winter, G., & Milstein, C. (1991) · Nature · doi:10.1038/349293a0 · Cited by 945
Therapeutic strategies for rheumatoid arthritis
Smolen, J. S., & Steiner, G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1109 · Cited by 911
Anatomy of the antibody molecule
Padlan, E. A. (1994) · Molecular Immunology · doi:10.1016/0161-5890(94)90001-9 · Cited by 896
Cited by
Properties, production, and applications of camelid single-domain antibody fragments
Harmsen, M. M., & De Haard, H. J. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1142-2 · Cited by 809
“Similar to conventional VH domains, VHHs contain four framework regions (FRs) that form the core structure of the immunoglobulin domain and three complementarity-determining regions (CDRs) that are involved in antigen binding.”
BackgroundNanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“As recombinant proteins, VHH are designated single-domain antibodies or nanobodies (4) in reference to their small size in the nanometer range (20, 21).”
BackgroundEmerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Kooijmans, S. A. A., Aleza, C. G., Roffler, S. R., van Solinge, W. W., Vader, P., & Schiffelers, R. M. (2016) · Journal of Extracellular Vesicles · doi:10.3402/jev.v5.31053 · Cited by 426
Van de Broek, B., Devoogdt, N., D’Hollander, A., Gijs, H.-L., Jans, K., Lagae, L., Muyldermans, S., Maes, G., & Borghs, G. (2011) · ACS Nano · doi:10.1021/nn1023363 · Cited by 374
Self-citation
Metadata
- Authors
- Revets, H., De Baetselier, P., & Muyldermans, S.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2005-01
- Volume
- 5
- Issue
- 1
- Pages
- 111-124
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2117218524
- Cited by
- 254
- References
- 130
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanobodies as novel agents for cancer therapy. https://app.cochat.ai/papers/10.1517/14712598.5.1.111
- The paper
- Revets, H., De Baetselier, P., & Muyldermans, S. (2005). Nanobodies as novel agents for cancer therapy. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.5.1.111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.